Regulation of the mouse gene encoding TAFI by TNFα

Role of NFκB binding site

Mathieu Garand, Joellen H H Lin, Ceredwyn E. Hill, Branislava Zagorac, Marlys L. Koschinsky, Michael B. Boffa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thrombin-activable fibrinolysis inhibitor (TAFI) is a plasma pro-carboxypeptidase, encoded by the gene CPB2, with roles in both inhibition of fibrinolysis and inflammation. In mice, plasma TAFI levels and hepatic CPB2 mRNA expression were found to increase within 24. h after intra-peritoneal lipopolysaccharide (LPS) injection. On the other hand, plasma TAFI in humans decrease in experimental endotoxemia and sepsis and we have previously demonstrated that CPB2 mRNA abundance in human hepatoma cells is decreased by inflammatory cytokines. Here, we have evaluated the effects of TNFα on mouse CPB2 expression. Treatment of primary mouse hepatocytes or the mouse hepatic cell line FL83B with TNFα for 12-48. h resulted in increases in CPB2 mRNA abundance of up to 2-fold; mouse TAFI protein levels secreted from FL83B cells increased 2.7-fold after 48. h treatment with TNFα. When FL83B cells were transfected with reporter plasmids containing the mouse CPB2 5'-flanking region, treatment with TNFα for 24 and 48. h resulted in a 1.5-fold increased mouse CPB2 promoter activity. Mutation of a putative NFκB site not conserved in the human gene ablated the increased promoter activity observed following TNFα treatment. This site binds NFκB as assessed by gel mobility shift assays, and TNFα treatment increases the translocation of NFκB from the cytoplasm to the nucleus of mouse hepatocytes. These results demonstrate that the unique NFκB site in the mouse CPB2 promoter is functional and mediates the upregulation of mouse CPB2 expression by TNFα via increase in NFκB translocation to the nucleus.

Original languageEnglish
Pages (from-to)389-397
Number of pages9
JournalCytokine
Volume57
Issue number3
DOIs
Publication statusPublished - 1 Mar 2012
Externally publishedYes

Fingerprint

Gene encoding
Fibrinolysis
Thrombin
Binding Sites
Plasmas
Messenger RNA
Genes
Carboxypeptidases
5' Flanking Region
Hepatocytes
Lipopolysaccharides
Assays
Plasmids
Gels
Cytokines
Therapeutics
Endotoxemia
Proteins
Electrophoretic Mobility Shift Assay
Hepatocellular Carcinoma

Keywords

  • Fibrinolysis
  • Inflammation
  • NFκB
  • Thrombin-activable fibrinolysis inhibitor (TAFI)
  • TNFα

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Hematology
  • Biochemistry
  • Molecular Biology

Cite this

Garand, M., Lin, J. H. H., Hill, C. E., Zagorac, B., Koschinsky, M. L., & Boffa, M. B. (2012). Regulation of the mouse gene encoding TAFI by TNFα: Role of NFκB binding site. Cytokine, 57(3), 389-397. https://doi.org/10.1016/j.cyto.2011.11.023

Regulation of the mouse gene encoding TAFI by TNFα : Role of NFκB binding site. / Garand, Mathieu; Lin, Joellen H H; Hill, Ceredwyn E.; Zagorac, Branislava; Koschinsky, Marlys L.; Boffa, Michael B.

In: Cytokine, Vol. 57, No. 3, 01.03.2012, p. 389-397.

Research output: Contribution to journalArticle

Garand, M, Lin, JHH, Hill, CE, Zagorac, B, Koschinsky, ML & Boffa, MB 2012, 'Regulation of the mouse gene encoding TAFI by TNFα: Role of NFκB binding site', Cytokine, vol. 57, no. 3, pp. 389-397. https://doi.org/10.1016/j.cyto.2011.11.023
Garand, Mathieu ; Lin, Joellen H H ; Hill, Ceredwyn E. ; Zagorac, Branislava ; Koschinsky, Marlys L. ; Boffa, Michael B. / Regulation of the mouse gene encoding TAFI by TNFα : Role of NFκB binding site. In: Cytokine. 2012 ; Vol. 57, No. 3. pp. 389-397.
@article{610c5673b75445d080bd548f0022c439,
title = "Regulation of the mouse gene encoding TAFI by TNFα: Role of NFκB binding site",
abstract = "Thrombin-activable fibrinolysis inhibitor (TAFI) is a plasma pro-carboxypeptidase, encoded by the gene CPB2, with roles in both inhibition of fibrinolysis and inflammation. In mice, plasma TAFI levels and hepatic CPB2 mRNA expression were found to increase within 24. h after intra-peritoneal lipopolysaccharide (LPS) injection. On the other hand, plasma TAFI in humans decrease in experimental endotoxemia and sepsis and we have previously demonstrated that CPB2 mRNA abundance in human hepatoma cells is decreased by inflammatory cytokines. Here, we have evaluated the effects of TNFα on mouse CPB2 expression. Treatment of primary mouse hepatocytes or the mouse hepatic cell line FL83B with TNFα for 12-48. h resulted in increases in CPB2 mRNA abundance of up to 2-fold; mouse TAFI protein levels secreted from FL83B cells increased 2.7-fold after 48. h treatment with TNFα. When FL83B cells were transfected with reporter plasmids containing the mouse CPB2 5'-flanking region, treatment with TNFα for 24 and 48. h resulted in a 1.5-fold increased mouse CPB2 promoter activity. Mutation of a putative NFκB site not conserved in the human gene ablated the increased promoter activity observed following TNFα treatment. This site binds NFκB as assessed by gel mobility shift assays, and TNFα treatment increases the translocation of NFκB from the cytoplasm to the nucleus of mouse hepatocytes. These results demonstrate that the unique NFκB site in the mouse CPB2 promoter is functional and mediates the upregulation of mouse CPB2 expression by TNFα via increase in NFκB translocation to the nucleus.",
keywords = "Fibrinolysis, Inflammation, NFκB, Thrombin-activable fibrinolysis inhibitor (TAFI), TNFα",
author = "Mathieu Garand and Lin, {Joellen H H} and Hill, {Ceredwyn E.} and Branislava Zagorac and Koschinsky, {Marlys L.} and Boffa, {Michael B.}",
year = "2012",
month = "3",
day = "1",
doi = "10.1016/j.cyto.2011.11.023",
language = "English",
volume = "57",
pages = "389--397",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Regulation of the mouse gene encoding TAFI by TNFα

T2 - Role of NFκB binding site

AU - Garand, Mathieu

AU - Lin, Joellen H H

AU - Hill, Ceredwyn E.

AU - Zagorac, Branislava

AU - Koschinsky, Marlys L.

AU - Boffa, Michael B.

PY - 2012/3/1

Y1 - 2012/3/1

N2 - Thrombin-activable fibrinolysis inhibitor (TAFI) is a plasma pro-carboxypeptidase, encoded by the gene CPB2, with roles in both inhibition of fibrinolysis and inflammation. In mice, plasma TAFI levels and hepatic CPB2 mRNA expression were found to increase within 24. h after intra-peritoneal lipopolysaccharide (LPS) injection. On the other hand, plasma TAFI in humans decrease in experimental endotoxemia and sepsis and we have previously demonstrated that CPB2 mRNA abundance in human hepatoma cells is decreased by inflammatory cytokines. Here, we have evaluated the effects of TNFα on mouse CPB2 expression. Treatment of primary mouse hepatocytes or the mouse hepatic cell line FL83B with TNFα for 12-48. h resulted in increases in CPB2 mRNA abundance of up to 2-fold; mouse TAFI protein levels secreted from FL83B cells increased 2.7-fold after 48. h treatment with TNFα. When FL83B cells were transfected with reporter plasmids containing the mouse CPB2 5'-flanking region, treatment with TNFα for 24 and 48. h resulted in a 1.5-fold increased mouse CPB2 promoter activity. Mutation of a putative NFκB site not conserved in the human gene ablated the increased promoter activity observed following TNFα treatment. This site binds NFκB as assessed by gel mobility shift assays, and TNFα treatment increases the translocation of NFκB from the cytoplasm to the nucleus of mouse hepatocytes. These results demonstrate that the unique NFκB site in the mouse CPB2 promoter is functional and mediates the upregulation of mouse CPB2 expression by TNFα via increase in NFκB translocation to the nucleus.

AB - Thrombin-activable fibrinolysis inhibitor (TAFI) is a plasma pro-carboxypeptidase, encoded by the gene CPB2, with roles in both inhibition of fibrinolysis and inflammation. In mice, plasma TAFI levels and hepatic CPB2 mRNA expression were found to increase within 24. h after intra-peritoneal lipopolysaccharide (LPS) injection. On the other hand, plasma TAFI in humans decrease in experimental endotoxemia and sepsis and we have previously demonstrated that CPB2 mRNA abundance in human hepatoma cells is decreased by inflammatory cytokines. Here, we have evaluated the effects of TNFα on mouse CPB2 expression. Treatment of primary mouse hepatocytes or the mouse hepatic cell line FL83B with TNFα for 12-48. h resulted in increases in CPB2 mRNA abundance of up to 2-fold; mouse TAFI protein levels secreted from FL83B cells increased 2.7-fold after 48. h treatment with TNFα. When FL83B cells were transfected with reporter plasmids containing the mouse CPB2 5'-flanking region, treatment with TNFα for 24 and 48. h resulted in a 1.5-fold increased mouse CPB2 promoter activity. Mutation of a putative NFκB site not conserved in the human gene ablated the increased promoter activity observed following TNFα treatment. This site binds NFκB as assessed by gel mobility shift assays, and TNFα treatment increases the translocation of NFκB from the cytoplasm to the nucleus of mouse hepatocytes. These results demonstrate that the unique NFκB site in the mouse CPB2 promoter is functional and mediates the upregulation of mouse CPB2 expression by TNFα via increase in NFκB translocation to the nucleus.

KW - Fibrinolysis

KW - Inflammation

KW - NFκB

KW - Thrombin-activable fibrinolysis inhibitor (TAFI)

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=84856372230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856372230&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2011.11.023

DO - 10.1016/j.cyto.2011.11.023

M3 - Article

VL - 57

SP - 389

EP - 397

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 3

ER -